Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.
about
Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in ratsIn vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with IntralipidAdministration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system.Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasisLiposomal amphotericin B therapy of murine histoplasmosis.Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patientsEfficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis.Carrier effects on biological activity of amphotericin B.Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.Amphotericin B lipid complex therapy of experimental fungal infections in miceEfficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine modelTissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers.Liposomes in the treatment of infections.Intralipid in prophylaxis of amphotericin B nephrotoxicity.Amphotericin B and its lipid formulations.Liposomes.Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B.Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model.A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.Tissue distribution of amphotericin B lipid complex in laboratory animals.Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.Distribution of free and liposome-encapsulated cefoxitin in experimental intra-abdominal sepsis in rats.
P2860
Q28333669-0B1AD5E5-9B97-4200-B91F-475EB8057916Q28369708-52EC5C98-F58E-44CD-A355-0AA28DF9FFC9Q33694095-4682361A-4B2C-4516-AAF4-2C7ADC0D56A3Q33697079-9D5E2833-8396-4678-AC0B-B1EEFE9C7ABCQ33749073-6568D575-4F15-446B-AE7B-862E2DBFE683Q33749615-BBDC29F4-5E35-420C-9542-C49D91C4C5C5Q33983629-A8C7B998-64A2-4408-894A-9BF78A967261Q34529190-1771A85A-E547-4BFD-922B-EC146D7526EDQ35117788-9DB958A3-DE36-42F6-9BF9-E581C20510C0Q35118084-B273D764-C3B3-47E8-866E-02ED0C1668C2Q35136556-DDFADEA5-0EBE-45B2-A96D-AB272D6CB332Q35270948-D7250941-C4DD-4CF7-926D-C7EF4175B362Q35372581-746CEFA7-46C3-4F51-999B-84EB0400CAA2Q36422661-AEBD0B74-0963-4C11-B06A-1F931810771AQ36753279-6259CFA2-27AB-4C76-89BF-FA62C019E942Q36758184-6D8208FD-338F-4286-903B-111DEFA36792Q39783583-BC692E2C-6EF4-426C-AE28-D16AE267DA99Q39784710-573A110D-CE44-46FC-A552-9F9415BF244DQ40222438-3F379902-0ED4-4268-8767-31A7099BFA9FQ40284175-60EA86F7-8333-4D09-A22D-D55EF2A936FBQ40499095-ECCBAC10-CC02-42D4-BA56-0FD5533DF807Q40582560-7353062B-29E6-4538-AF99-39A84D278AAAQ40626316-620E63BE-017C-4F74-AE8D-743BF20BF244Q41208681-B7A04014-98AB-45F1-BDD3-C8A35AA78740Q44423028-DCDD6B7F-E416-4BE6-B151-C19A408E1E57Q45886453-095C6F43-303F-442B-B769-67715E1E6729Q50084493-73950355-C2BD-4645-8C6A-DB3603D68565Q50799275-29B082DA-3B39-4459-BBF6-79805FF48454Q51771412-6E9ACF37-D168-4DEF-85A1-AE77DB1F91B2Q54652390-664271B0-7788-4546-918B-97B0A8A06CFF
P2860
Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Therapeutic evaluation of free ...... systemic candidiasis in mice.
@en
Therapeutic evaluation of free ...... systemic candidiasis in mice.
@nl
type
label
Therapeutic evaluation of free ...... systemic candidiasis in mice.
@en
Therapeutic evaluation of free ...... systemic candidiasis in mice.
@nl
prefLabel
Therapeutic evaluation of free ...... systemic candidiasis in mice.
@en
Therapeutic evaluation of free ...... systemic candidiasis in mice.
@nl
P2093
P2860
P356
P1476
Therapeutic evaluation of free ...... systemic candidiasis in mice.
@en
P2093
P2860
P304
P356
10.1128/AAC.33.9.1544
P407
P577
1989-09-01T00:00:00Z